Cellares and TScan Therapeutics agreed to evaluate automated manufacturing for TSC-101, TScan’s TCR-T therapy candidate designed for patients with AML and MDS undergoing allogeneic hematopoietic cell transplantation. The evaluation focuses on scaling and stabilizing manufacturing consistency as TScan moves toward a pivotal trial expected to start in Q2 2026. Under the agreement, Cellares will automate TSC-101 manufacturing and testing on its Cell Shuttle end-to-end platform, supported by Cell Q automated quality control and release testing. The companies said closed-system workflows are intended to reduce process variability and labor intensity. The effort signals growing pressure across cell therapy to industrialize release testing and reduce operational bottlenecks for broader patient access.